{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:14:14Z","timestamp":1773785654222,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to examine the utility of macular volume (MV), central retinal thickness (CRT), and their fluctuations for predicting post-treatment visual acuity in patients with macular edema (ME) secondary to retinal vein occlusion (RVO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective cohort study included patients treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for ME due to RVO at a tertiary university hospital between August 2016 and July 2020. We identify the correlation of the MV, CRT, with their fluctuations, and best-corrected visual acuity (BCVA) measured using optical coherence tomography at baseline and at 1-, 3-, 6-, and 12-months post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 74 eyes included, 27 and 47 had central RVO (CRVO) and branch RVO (BRVO), respectively. Following anti-VEGF therapy both, the CRVO and BRVO group exhibited significant improvements in BCVA, CRT, and MV compared to baseline. In all patients, MV was consistently correlated with BCVA, whereas CRT was correlated with BCVA at selected time points. In patients with CRVO, MV was a better predictor of post-treatment visual outcomes than CRT. Moreover, fluctuations in CRT and MV correlated with BCVA over 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>MV yielded more correlation with visual outcomes in patients with RVO and ME receiving anti-VEGF therapy than CRT. Considering concurrent MV and CRT measurements could enhance more precision of treatment assessment, especially in CRVO patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00693-2","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:43:02Z","timestamp":1750070582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation of retinal thickness, macular volume, and their fluctuation with visual outcomes in patients with macular edema due to retinal vein occlusion"],"prefix":"10.1186","volume":"11","author":[{"given":"Kwanchanok","family":"Rattanalert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-1941","authenticated-orcid":false,"given":"Patama","family":"Bhurayanontachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansing","family":"Ratanasukon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pichai","family":"Jirarattanasopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wantanee Dangboon","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"693_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313\u20139. e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"key":"693_CR2","doi-asserted-by":"publisher","unstructured":"Baseline and early natural history report. The central vein occlusion study arch ophthalmol. 1993;111:1087\u201395. https:\/\/doi.org\/10.1001\/archopht.1993.01090080083022","DOI":"10.1001\/archopht.1993.01090080083022"},{"key":"693_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209\u201319. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.038","journal-title":"Ophthalmology"},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/bjophthalmol-2020-315836","volume":"105","author":"R Gale","year":"2021","unstructured":"Gale R, Pikoula M, Lee AY, Denaxas S, Egan C, Tufail A, et al. Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser. Br J Ophthalmol. 2021;105:549\u201354. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315836","journal-title":"Br J Ophthalmol"},{"key":"693_CR5","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal Aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the copernicus study. Ophthalmology. 2014;121:1414\u2013e14201. https:\/\/doi.org\/10.1016\/j.ophtha.2014.01.027","journal-title":"Ophthalmology"},{"key":"693_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/aos.14621","volume":"99","author":"M Michl","year":"2021","unstructured":"Michl M, Liu X, Kaider A, Sadeghipour A, Gerendas BS, Schmidt-Erfurth U. The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion. Acta Ophthalmol. 2021;99:418\u201326. https:\/\/doi.org\/10.1111\/aos.14621","journal-title":"Acta Ophthalmol"},{"key":"693_CR7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/OPTH.S110793","volume":"10","author":"A Fujihara-Mino","year":"2016","unstructured":"Fujihara-Mino A, Mitamura Y, Inomoto N, Sano H, Akaiwa K, Semba K. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol. 2016;10:1305\u201313. https:\/\/doi.org\/10.2147\/OPTH.S110793","journal-title":"Clin Ophthalmol"},{"key":"693_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.oret.2021.02.008","volume":"5","author":"P Sen","year":"2021","unstructured":"Sen P, Gurudas S, Ramu J, Patrao N, Chandra S, Rasheed R, et al. Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol Retina. 2021;5:1115\u201324. https:\/\/doi.org\/10.1016\/j.oret.2021.02.008","journal-title":"Ophthalmol Retina"},{"key":"693_CR9","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00417-022-05697-4","volume":"260","author":"SZ Gu","year":"2022","unstructured":"Gu SZ, Nanegrungsunk O, Bressler SB, Du W, Amer F, Moini H, et al. Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion: post hoc analysis of Copernicus, Galileo, and Vibrant. Graefes Arch Clin Exp Ophthalmol. 2022;260:3799\u2013807. https:\/\/doi.org\/10.1007\/s00417-022-05697-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"693_CR10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.oret.2020.05.018","volume":"4","author":"AX Chen","year":"2020","unstructured":"Chen AX, Greenlee TE, Conti TF, Briskin IN, Singh RP. Fluctuations in macular thickness in patients with retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmol Retina. 2020;4:1158\u201369. https:\/\/doi.org\/10.1016\/j.oret.2020.05.018","journal-title":"Ophthalmol Retina"},{"key":"693_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000002864","journal-title":"Anesth Analg"},{"key":"693_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3928\/23258160-20220215-03","volume":"53","author":"JC Muste","year":"2022","unstructured":"Muste JC, Iyer AI, Kalur A, Talcott KE, Singh RP. The quantification and impact of persistent retinal fluid compartments on best-corrected visual acuity of patients with retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2022;53:139\u201347. https:\/\/doi.org\/10.3928\/23258160-20220215-03","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"693_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00417-021-05494-5","volume":"260","author":"IU Scott","year":"2022","unstructured":"Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Investigator Group. SCORE2 report 17: macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2022;260:1491\u2013500. https:\/\/doi.org\/10.1007\/s00417-021-05494-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00693-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:43:03Z","timestamp":1750070583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00693-2","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Faculty of Medicine, Prince of Songkla University. The data extraction and data analysis processes were conducted in accordance with the Personal Data Protection Act (PDPA). Informed consents were waived due to minimal or no risk to the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}